A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

This is a two-arm, randomized, double-blinded, multicenter phase III clinical study to evaluate the efficacy of HLX10 combined with chemotherapy versus placebo combined with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer.

Subjects will be randomized to the following two arms at 1: 1 ratio:

• Arm A (HLX10 arm): HLX10 combined with chemotherapy will be adopted in the neoadjuvant treatment phase, and HLX10 monotherapy will be administered in the adjuvant treatment phase;
• Arm B (control arm): Placebo combined with chemotherapy will be given in the neoadjuvant treatment phase, and chemotherapy alone will be administered during the adjuvant treatment phase.

Chemotherapy regimen SOX (oxaliplatin + tegafor gimeracil oteracil potassium (S-1)) will be used in the neoadjuvant treatment phase in Arm A and B, and in the adjuvant treatment phase in Arm B.

After randomization, subjects will receive a total of 3 cycles of neoadjuvant treatment with the mentioned treatment regimen.Surgery will be performed within 3-6 weeks after the last cycle of neoadjuvant treatment.All subjects who have completed the surgery will be unblinded after surgery, and adjuvant treatment will be started 3 to 12 weeks after surgery. Subjects randomized to Arm A (HLX10 arm) will continue to receive HLX10 monotherapy for up to 17 cycles (12 months).Subjects in Arm B after surgery (control arm) will continue to use chemotherapy alone (oxaliplatin + S-1) for 5 cycles.

Study Overview

• Status: Recruiting
• Conditions: Gastric Cancer
• Intervention / Treatment: Drug: HLX10; Drug: Placebos

• Study Type: Interventional
• Enrollment (Anticipated): 642
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Jiafu JI; Phone Number: 010-88140650; Email: jijiafu@hsc.pku.edu.cn

Study Locations

• China
  • Baoding, China
    • Recruiting
    • Affiliated Hospital of Hebei University
    • Contact: Aimin Zang, MD
  • Beijing, China
    • Recruiting
    • Peking University Third Hospital
    • Contact: Baoshan Cao, MD
  • Beijing, China
    • Recruiting
    • Beijing Cancer Hospital
    • Contact: Jiafu JI; Phone Number: 01088140650; Email: jijiafu@hsc.pku.edu.cn
  • Beijing, China
    • Recruiting
    • China PLA General Hospital
    • Contact: Lin Chen, MD
  • Beijing, China
    • Recruiting
    • Peking University International Hospital
    • Contact: Jun Liang, MD
  • Bengbu, China
    • Recruiting
    • The First Affiliated Hospital of Bengbu Medical College
    • Contact: Congqiao Jiang, MD
  • Cangzhou, China
    • Recruiting
    • Cangzhou People's Hospital
    • Contact: Yuankai Bo, MD
  • Hefei, China
    • Recruiting
    • Anhui Provincial Hospital
    • Contact: Zhiqiang Zhu, MD
    • Contact: Gang Wang, MD
  • Hefei, China
    • Recruiting
    • The First Affiliated Hospital of Anhui Medical University
    • Contact: Guoping Sun, MD
  • Linyi, China
    • Recruiting
    • Linyi Cancer Hospital
    • Contact: Qingxu Sun, MD
  • Shijia Zhuang, China
    • Recruiting
    • The Fourth Hospital of Hebei Medical University
  • Taiyuan, China
    • Recruiting
    • Shanxi Provincial People's Hospital
    • Contact: Xiaogang Bi, MD
  • Tianjin, China
    • Recruiting
    • Tianjin Medical University Institute & Hospital
    • Contact: Yi Ba, MD
  • Xingtai, China
    • Recruiting
    • Xingtai People's Hospital
    • Contact: Zhibin Huo, MD
  • Guangdong
    • Shenzhen, Guangdong, China
      • Recruiting
      • Peking University Shenzhen Hospital
      • Contact: Shu bin Wang; Phone Number: 13823394076; Email: Wangshubin2013@163.com
      • Principal Investigator: Shu bin Wang

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Voluntary participation in the clinical study; fully understands and is informed of the study and has signed the Informed Consent Form (ICF); willing to comply with and able to complete all trial procedures.
2. The gender is not limited. When ICF is signed, the age is ≥ 18 years and ≤ 70 years old.
3. Histologically confirmed untreated gastric cancers, mainly adenocarcinoma.
4. Within 4 weeks prior to first dose, determined by the Independent Radiology Review Committee (IRRC) as: ≥ T3 and number of lymph node metastases ≥ 1 and no distant metastasis.
5. Prior to enrollment, the attending physician will evaluate to determine the eligibility for a R0 resection for the purpose of radical treatment.
6. Have good cardiac function and can be treated with radical resection.
7. tumor specimen testing results are PD-L1 positive (CPS ≥5). Subjects must provide the tumor tissues at screening or in the investigated surgery (if any), for PD-L1 expression level assessment.
8. Within 7 days before the first use of the study drug, ECOG: 0 ~ 1;
9. Expected survival 12 weeks;
10. The functions of the vital organs meet requirements.

Exclusion Criteria:

1. Existence of other active malignant tumors within 5 years or at the same time.
2. Plan to perform or have undergone an organ or bone marrow transplant.
3. Myocardial infarction and poorly controlled arrhythmias occurred within 6 months prior to the first dose.
4. Existence of grade III - IV cardiac disorders defined by the NYHA or echocardiogram shows: LVEF (left ventricular ejection fraction) < 50%.
5. Human immunodeficiency virus (HIV) infection.
6. Patients with active tuberculosis.
7. Patient with previous or current interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-associated pneumonia, severely impaired lung function, etc.
8. Patients who have previously received other antibody/drug treatments for immune checkpoints, such as PD-1, PD-L1, and CTLA4 treatments.
9. Have diseases that may increase the risk of participating in the study and using the study medications, or other severe, acute, and chronic diseases and therefore are judged by the investigator to be unsuitable for clinical studies.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: HLX10; HLX10 combined with chemotherapy will be adopted in the neoadjuvant treatment phase, and HLX10 monotherapy will be administered in the adjuvant treatment phase	Drug: HLX10; neoadjuvant treatment phase：HLX10（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：HLX10（4.5mg/kg/3w IV）; Other Names: Recombinant humanized anti-PD-1 monoclonal antibody injection
Placebo Comparator: Placebo; Placebo combined with chemotherapy will be given in the neoadjuvant treatment phase, and chemotherapy alone will be administered during the adjuvant treatment phase.	Drug: Placebos; neoadjuvant treatment phase：placebos（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：SOX

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
EFS	event-free survival (assessed by independent radiological review committee (IRRC) based on RECIST v1.1)	from randomizationuntil firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 3 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
EFS	Event-free survival (assessed by the investigator per RECIST v1.1 criteria)	from randomizationuntil firstly confirmed and recorded disease progression or death (whichever occurs earlier)，assessed up to 3 years
DFS	Disease-free survival (assessed by the investigator per RECIST v1.1 criteria)	from the start of surgery to disease recurrence or death (for any reason)，assessed up to 3 years
pCR rate	Pathological complete response (pCR) rate (assessed by central pathology laboratory and the site)	after surgery，an average of 6 months
5-year OS rate	5-year overall survival (OS) rate	OS is the time from randomization to death (of any cause)，assessed up to 5 years

Collaborators and Investigators

• Sponsor: Shanghai Henlius Biotech

Study record dates

Study Major Dates

• Study Start (Actual): December 12, 2019
• Primary Completion (Anticipated): October 1, 2023
• Study Completion (Anticipated): October 1, 2024

Study Registration Dates

• First Submitted: October 16, 2019
• First Submitted That Met QC Criteria: October 23, 2019
• First Posted (Actual): October 25, 2019

Study Record Updates

• Last Update Posted (Actual): June 6, 2022
• Last Update Submitted That Met QC Criteria: June 1, 2022
• Last Verified: June 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Stomach Diseases; Stomach Neoplasms
• Other Study ID Numbers: HLX10-006-GCneo

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No